Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "1"

Discover Series: Diabetes

What would you discover to help a child? At The Kids, our researchers are committed to Type 1 Diabetes research that makes a real difference.

The Cashew Study

Does eating cashew nut spreads in the first year of life reduce the chances a baby will develop a cashew nut food allergy?

News & Events

Dr Amelia Harray on ABC Radio

Did you hear our head of nutrition research Dr Amelia Harray on ABC Radio recently? Listen to Amelia discuss tips to limit sugar on Halloween PLUS

Research

Variation in nutrition education practices in SWEET pediatric diabetes centers-an international comparison

Nutrition education is central to pediatric type 1 diabetes management. Dietary management guidelines for type 1 diabetes are evidence based, but implementation may be challenging and inconsistent. We describe variation in the practice of nutrition education across pediatric diabetes centers globally and explore associations with A1c and BMI.

Publications

Browse the published work of the Centre's researchers

News & Events

Perth's active T1D community

Despite the unseasonal weather, good turnouts were recorded for recent events organised by PMH and Diabetes WA.

Research

Resilience and Diabetes 2 (the RAD2 study)

Investigators: Anna Hunt, Ashleigh Lin  Stress and anxiety are significant problems in children and adolescence with type 1 diabetes. Not only do

Research

Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD

Mitophagy preserves overall mitochondrial fitness by selectively targeting damaged mitochondria for degradation. The regulatory mechanisms that prevent PTEN-induced putative kinase 1 (PINK1) and E3 ubiquitin ligase Parkin (PINK1/Parkin)-dependent mitophagy and other selective autophagy pathways from overreacting while ensuring swift progression once initiated are largely elusive. 

Research

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE

The pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.

News & Events

Good news for students

The Children’s Diabetes Centre welcomes a new Federal Government initiative to support children with Type 1 Diabetes in schools. The two-year $6 million schools education and training program will be implemented at every school with a student with Type 1 Diabetes.